Notably, we demonstrate that differential core and marginal CD4+ cell quantifications of whole tumor tissues derived from patients with non–small cell lung cancer (NSCLC) after neoadjuvant αPD-L1 therapy were predictive of therapy resistance. The gene discussed is CD4; the disease is lung cancer.